Literature DB >> 17719279

Validation of the Italian version of the Cystic Fibrosis Quality of Life Questionnaire (CFQoL), a disease specific measure for adults and adolescents with cystic fibrosis.

Fiorella Monti1, Francesca Lupi, Francesca Gobbi, Francesca Agostini, Angelo Miano, Louise Gee, Janice Abbott.   

Abstract

BACKGROUND: Disease specific, health-related quality of life (HRQoL) measurement is important in cystic fibrosis (CF). This work aimed to translate the original English Cystic Fibrosis Quality of Life Questionnaire (CFQoL) into Italian, evaluate the linguistic translation and to psychometrically evaluate the Italian version of the CFQoL.
METHODS: The linguistic translation followed the international guidelines of forward and backward translation. Psychometric evaluation of the Italian CFQoL involved the assessment of construct validity, internal reliability, concurrent validity, known groups validity and test-retest reliability.
RESULTS: The instrument was acceptable to adolescents and adults with CF and demonstrated robust psychometric properties. Principle components analysis indicated that the factorial structure was essentially similar to the original, and the internal reliability of each domain was good (Cronbach alpha coefficients 0.73 to 0.91). Appropriate domains of the CFQoL and SF-36 correlated well indicating good concurrent validity (r=0.68-0.80). Consistent with theoretical expectations some domains were able to discriminate between disease severity groups. Test-retest reliability, assessed by intraclass correlation coefficients, was found to be excellent (ICC 0.83 to 0.98).
CONCLUSIONS: The Italian CFQoL is a valid and reliable measure. Its use in individual patient monitoring and research should complement traditional clinical outcome measures.

Entities:  

Mesh:

Year:  2007        PMID: 17719279     DOI: 10.1016/j.jcf.2007.06.003

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  6 in total

1.  How about your peers? Cystic fibrosis questionnaire data from healthy children and adolescents.

Authors:  Marijke M Tibosch; Coosje J J C M Sintnicolaas; Jeannette B Peters; Peter J F M Merkus; Jan-Bart L Yntema; Christianne M Verhaak; Jan H Vercoulen
Journal:  BMC Pediatr       Date:  2011-10-11       Impact factor: 2.125

2.  Validity evidence and reliability of a simulated patient feedback instrument.

Authors:  Claudia Schlegel; Ulrich Woermann; Jan-Joost Rethans; Cees van der Vleuten
Journal:  BMC Med Educ       Date:  2012-01-27       Impact factor: 2.463

3.  Do patient-reported outcomes have a role in the management of patients with cystic fibrosis?

Authors:  M Sam Salek; S Jones; M Rezaie; C Davies; R Mills; R I Ketchell
Journal:  Front Pharmacol       Date:  2012-03-12       Impact factor: 5.810

4.  Factors related to changes in the quality of life among Polish adolescents and adults with cystic fibrosis over a 1-year period.

Authors:  Grażyna Dębska; Henryk Mazurek
Journal:  Patient Prefer Adherence       Date:  2015-12-15       Impact factor: 2.711

Review 5.  Antioxidant supplementation for lung disease in cystic fibrosis.

Authors:  Oana Ciofu; Sherie Smith; Jens Lykkesfeldt
Journal:  Cochrane Database Syst Rev       Date:  2019-10-03

6.  Psychometric evaluation of the Swedish translation of the revised Cystic Fibrosis Questionnaire in adults.

Authors:  Jacek Hochwälder; Agneta Bergsten Brucefors; Lena Hjelte
Journal:  Ups J Med Sci       Date:  2016-09-15       Impact factor: 2.384

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.